Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Combined With Cisplatin in Recurrent or Metastatic Breast Cancer
NCT06900647Phase 1Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of bortezomib in breast cancer (6 arms), sponsored by Sun Yat-sen University. Primary endpoints: Dose-limiting toxicities at 28 days and Maximum Tolerated Dose at 28 days. Started Jan 2025; status: recruiting.
02
Drugs
bortezomib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06900647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900647.